|
Press Releases |
|
 |
|
Monday, August 17, 2020 |
|
拜耳与华领医药宣布在糖尿病领域建立战略合作 双方就处于临床试验阶段的首创糖尿病治疗药物dorzagliatin在中国达成商业合作协议 |
拜耳今天宣布与领先的创新药物研发公司华领医药建立战略合作,就新型糖尿病治疗药物dorzagliatin在中国达成商业合作协议。此项协议将发挥拜耳在中国糖尿病管理领域的领先优势以及华领医药的创新能力,为中国糖尿病患者提供全新的治疗方案选择。 more info >> |
|
拜耳與華領醫藥宣佈在糖尿病領域建立戰略合作 雙方就處於臨床試驗階段的首創糖尿病治療藥物dorzagliatin在中國達成商業合作協議 |
拜耳今天宣佈與領先的創新藥物研發公司華領醫藥建立戰略合作,就新型糖尿病治療藥物dorzagliatin在中國達成商業合作協議。此項協議將發揮拜耳在中國糖尿病管理領域的領先優勢以及華領醫藥的創新能力,為中國糖尿病患者提供全新的治療方案選擇。 more info >> |
|
Bayer and Hua Medicine announce commercialization agreement and strategic partnership for investigational first-in-class novel diabetes treatment dorzagliatin in China |
Bayer and Hua Medicine, a leading innovative drug development company, today announced a commercialization agreement and strategic partnership for dorzagliatin, a novel diabetes treatment, in China. more info >> |
|
Wednesday, July 1, 2020 |
|
华领医药宣布Dorzagliatin与二甲双胍联合用药III期注册临床研究24周核心研究取得正面结果 |
华领医药今天宣布其在中国开展的全球首创新药葡萄糖激酶激活剂dorzagliatin与二甲双胍(2型糖尿病全球一线用药)联合用药III期注册临床研究(HMM0302)的24周核心研究的正面结果。 more info >> |
|
華領醫藥宣佈Dorzagliatin與二甲雙胍聯合用藥III期註冊臨床研究24週核心研究取得正面結果 |
華領醫藥今天宣佈其在中國開展的全球首創新藥葡萄糖激酶激活劑dorzagliatin與二甲雙胍(2型糖尿病全球一線用藥)聯合用藥III期註冊臨床研究(HMM0302)的24週核心研究的正面結果。 more info >> |
|
Hua Medicine Announces Positive 24-Week Topline Results of Phase III Metformin Combination Trial of Dorzagliatin |
Hua Medicine today announced the positive 24-week top-line results from HMM0302, a Phase III registration trial in China of its global first-in-class glucokinase activator dorzagliatin add-on to metformin, a first line oral antidiabetic therapy in Type 2 diabetes. more info >> |
|
Thursday, June 18, 2020 |
|
Hua Medicine Successfully Completes SEED (HMM0301), Dorzagliatin Phase III Monotherapy Trial |
Hua Medicine (the "Company", Stock Code: 2552.HK), a leading innovative drug development company focused on developing novel therapies for the treatment of diabetes, today announced topline results from SEED (also known as HMM0301) more info >> |
|
Monday, April 27, 2020 |
|
华领医药宣布Dorzagliatin与恩格列净(一种SGLT-2抑制剂)联合用药临床研究的成功结果 |
华领医药技术(上海)有限公司(以下简称「华领医药」,香港联交所股份代号:2552.HK)宣布临床研究HMM0112的成功结果。 more info >> |
|
華領醫藥宣佈Dorzagliatin與恩格列淨(一種SGLT-2抑制劑)聯合用藥臨床研究的成功結果 |
華領醫藥技術(上海)有限公司(以下簡稱「華領醫藥」,香港聯交所股份代號:2552.HK)宣佈臨床研究HMM0112的成功結果。 more info >> |
|
Hua Medicine Announces Positive Results in the Combination Study of Dorzagliatin with Empagliflozin (a SGLT-2 inhibitor) |
Hua Medicine (the "Company", Stock Code: 2552. HK) today announces the positive results of the clinical study HMM0112. more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
EdgePoint Towers Appoints Ravin Vickneswaran as Chief Operating Officer
Apr 7, 2025 03:06 HKT/SGT
|
|
|
2024年華泰證券營收創新高 累計分紅46.94億元
Apr 6, 2025 22:30 HKT/SGT
|
|
|
Fosun's Core Businesses Stay Firm Despite One-off Non-cash Loss
Apr 6, 2025 20:30 HKT/SGT
|
|
|
《周遊記3》開播 背後「隱藏玩家」巨星傳奇再造頂流綜藝IP
Apr 6, 2025 19:45 HKT/SGT
|
|
|
雲康集團2024年醫聯體共建業務及特檢項目收益佔比持續增長
Apr 6, 2025 18:27 HKT/SGT
|
|
|
Smart Lighting Expo and Spring Lighting Fair open today
Apr 6, 2025 16:55 HKT/SGT
|
|
|
ForexRova Debuts at International Forex Conference, Promises Smarter Gold Trading Solutions
Apr 5, 2025 19:00: JST
|
|
|
ForexRova Debuts at International Forex Conference, Promises Smarter Gold Trading Solutions
Apr 5, 2025 18:00 HKT/SGT
|
|
|
Connect Marketplace Hong Kong 2025 Concludes, Successfully Ushering in a New Era for MICE in the City
Apr 4, 2025 0:00 JST
|
|
|
JF SmartInvest Holdings Ltd Announces 2024 Annual Results
Apr 4, 2025 22:48 HKT/SGT
|
|
|
The India Market Entry Dilemma: What's Holding Manufacturers Back
Apr 4, 2025 22:08 HKT/SGT
|
|
|
3rd Future Cross Border Payments Summit, Dubai 2025: Trends Shaping the Future of Payments
Apr 4, 2025 21:15 HKT/SGT
|
|
|
CISO Indonesia 2025: Elevating Cybersecurity Strategies for a Resilient Digital Future
Apr 4, 2025 20:50 HKT/SGT
|
|
|
analytica Vietnam 2025 Opens Tomorrow: The Leading Laboratory Exhibition Returns to Vietnam
Apr 4, 2025 20:40 HKT/SGT
|
|
|
Kirin and Hitachi begin joint research on the creation of forest-based carbon credits
Apr 4, 2025 15:56 JST
|
|
|
|
More News >> |
|
|
|
|
|